Oligomerix is a biotechnology company focused on developing disease-modifying and treatment therapeutics for neurodegenerative diseases characterized by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy dementia to Alzheimer’s disease. Read More
Location: United States, New York, White Plains
Member count: 11-50
Total raised: $15.36M
Founded date: 2006
Funding Rounds 6
| Date | Series | Amount | Investors | Deal News |
| 05.06.2022 | Series B | $2.7M | - | finsmes.co... |
| 15.09.2020 | Grant | $3.19M | - | - |
| 10.10.2019 | Grant | $2.18M | - | - |
| 02.10.2018 | Grant | $2.49M | - | - |
| 22.05.2013 | Series B | $2.8M | - | finsmes.co... |
| 23.04.2012 | Series A | $2M | - | finsmes.co... |
Mentions in press and media 5
| Date | Title | Description | Category | Author | Source |
| 05.06.2022 | Oligomerix... | Oligomerix, a White Plains, Ne... | USA | - | finsmes.co... |
| 15.04.2015 | Startup ra... | Small molecule inhibitors of t... | - | - | medcitynew... |
| 22.05.2013 | Oligomerix... | Oligomerix, Inc., a New York, ... | funding U... | - | finsmes.co... |
| 23.04.2012 | Oligomerix... | Oligomerix, Inc., a company th... | funding U... | - | finsmes.co... |
| - | Startup ra... | Protein misfolding – and resul... | - | - | medcitynew... |